Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?
Shakespeare, Thomas, Aherne, Noel, Wilcox, SheaLanguage:
english
Journal:
OncoTargets and Therapy
DOI:
10.2147/OTT.S105174
Date:
May, 2016
File:
PDF, 420 KB
english, 2016